Skip to content

The David H. Koch Institute for Integrative Cancer Research At MIT

About

  • Director's Message
  • Future
  • Scientific Advisory Board
  • FAQs
  • Administration

Faculty

Research Areas

  • Nanotechnology Therapy
  • Detection and Monitoring
  • Metastasis
  • Pathways and Resistance
  • Immune System

facilities

  • The Koch Institute
  • Core Facilities

News and Events

  • Press Kit
  • Summer Symposium

Contact

Support

  • Make a Gift Now
  • Naming Opportunities
  • Bequests and Trusts
  • Corporate Giving
  • Gifts of Stock
  • Gifts of Other Assets

About the Koch Institute

  • Director's Message
  • Future
  • Scientific Advisory Board
  • FAQs
  • Administration

A New Institute With a Three-Decade Track Record

The David H. Koch Institute for Integrative Cancer Research at MIT both transforms and transcends the MIT Center for Cancer Research (CCR). Founded in 1974 by Nobel Laureate and MIT Professor Salvador Luria, CCR has made enormous contributions to the field of cancer research, including:

  • Identified the molecules that led to two of the first FDA-approved molecularly targeted anti-cancer drugs: Herceptin® (1998) and Gleevec® (2001)
  • Isolated the first human cancer genes
  • Discovered extracellular matrix components and their receptors, which play a critical role in metastasis
  • Contributed to the sequencing of the human genome
  • Developed novel materials for sustained delivery of anti-cancer drugs

CCR/Koch remains one of only eight National Cancer Institute-designated basic research centers in the US. And our faculty have earned the most prestigious national and international science honors:

  • Five current and former faculty have been awarded the Nobel Prize
  • 14 current faculty are members of the National Academy of Sciences
  • Six current and former faculty have been awarded the National Medal of Science
  • Five current faculty are Howard Hughes Medical Institute Investigators

About David H. Koch and the establishment of the Koch Institute... more >>

leadership council
David H. Koch, Chair Director & Executive Vice President Koch Industries
     
members
Janice Bourque Sr VP & Group Head Life Sciences Comerica Bank
Earl Collier, Jr Executive Vice President Genzyme Corporation
Janis Fraser Principal Fish & Richardson P.C.
Stephen Friend Executive Vice President Merck Research Laboratories
Nick G. Galakatos Co-founder & Managing Director Clarus Ventures
James Goodwin Principal James Goodwin, Inc.
Louise Grochow Senior Director, Clinical Research AstraZeneca
William M. Haney III Partner Uncommon Productions
Peter Hecht CEO Microbia
Diana Mackie Owner Health Matters!
Terrance McGuire Co-founder & Managing General Partner Polaris Venture Partners
Fred Middleton Managing Director Sanderling Biomedical Venture Capital
Barbara Piette President Knightsbridge
Richard Sackler Co-Chairman Purdue Pharma, L.P.
Stephen Scaringe Founder Dharmacon
Alison Taunton-Rigby Founder & CEO RiboNovix, Inc
Marty Tenenbaum Founder & Chairman CommerceNet
Heidi Wyle Founding CEO Computational Biology Corporation

Phillip A. Sharp

Phillip A. Sharp, Institute Professor (Nobel Laureate, 1993) circa 1980

 

 

Chip-based device

Our new, ultra-sensitive chip-based devices allow us to study changes in nanoparticles or living cells with over one million times greater precision than ever before.